Compass Inc Class A COMP 深 沪
等待开盘 01-08 09:30:00 美东时间
11.84
+1.010
+9.33%
华盛通- 最 高12.58
- 今 开11.80
- 成交量 1.03亿股
- 最 低 11.335
- 昨 收 10.83
- 总市值 66.07亿
- 52周最高 12.58
- 市盈率 静 --
- 换手率 18.51%
- 52周最低 5.655
- 委 比 9.52%
- 总股本 5.58亿
- 历史最高 22.11
- 量 比 12.95
- 振 幅 11.50%
- 历史最低 1.815
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BTIG Maintains Buy on Compass, Raises Price Target to $15
BTIG analyst Jake Fuller maintains Compass (NYSE:COMP) with a Buy and raises the price target from $12.5 to $15.
今天 18:12
Compass and Anywhere Stockholders Overwhelmingly Approve Merger
NEW YORK and MADISON, N.J., Jan. 7, 2026 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) ("Compass") and Anywhere Real Estate Inc. (NYSE: HOUS) ("Anywhere") announce that stockholders of each com...
今天 04:37
Compass Stock Rebounds After Early Drop On $750M Convertible Notes Offering
Compass shares are popping on Wednesday after an early dip sparked by dilution concerns
今天 02:55
Compass Therapeutics Provides Corporate Update
Compass Therapeutics provided updates on its pipeline, including tovecimig's Phase 2/3 study in biliary tract cancer with PFS and OS analyses expected in late Q1 2026. CTX-8371 showed durable responses in Hodgkin lymphoma and triple negative breast cancer, with cohort expansions underway. CTX-10726's Phase 1 study is set to begin in Q1 2026. The company expanded its leadership team with the appointment of Arjun Prasad as Chief Commercial Officer ...
01-06 13:00
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care
William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and reach over $1 billion in global sales.
01-06 02:06
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics granted stock options to its new Chief Commercial Officer, Arjun Prasad, and Chief Medical Officer, Cynthia Sirard, under its 2025 Inducement Plan. Each received options to purchase 1,000,000 shares at $5.17 per share, vesting over four years. The grants were approved by the Compensation Committee as material inducements to employment. Compass Therapeutics focuses on developing antibody-based therapeutics to treat cancers by ...
01-05 21:30
Compass Therapeutics Announces Key Leadership Appointments
Compass Therapeutics has appointed Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, effective January 1, 2026. With decades of experience in oncology product launches and clinical development, they bring expertise in advancing therapies for biliary tract cancer and other oncology indications. Prasad, previously at Servier and Agios, has successfully launched multiple oncology products, including ...
01-05 13:00
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Maze Therapeutics, Inc. announced that its CEO, Jason Coloma, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be live and available on the company's website for 30 days. Maze Therapeutics is a biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, utilizing its Compass™ platform. The company's pipeline includes MZE829...
01-05 12:00
Real estate stocks: What to expect in 2026
As widely expected, returns across real estate subsectors varied significantly in 2025. While the S&P 500 real estate sector ended the year in red against the broader S&P 500’s ~16% gain, health care ...
01-04 01:26
The best performing real estate stocks YTD
The real estate sector (XLRE) has produced some impressive winners across various sub-industries, from real estate services firms to healthcare REITs. However, the sector as a whole has not seen a lot...
2025-12-30 20:48
